Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead cMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.33
Change (%) Stock is Up 0.04 (3.10%)
Volume1,667,597
Data as of 12/26/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
12/15/14Exelixis’ Collaborator Genentech Files New Drug Application for the Combination of Cobimetinib and Vemurafenib for the Treatment of Patients With BRAF V600 Mutation-Positive Advanced MelanomaPrinter Friendly Version
12/01/14Exelixis Announces Results from the COMET-2 Pivotal Phase 3 Trial of Cabozantinib in Men With Metastatic Castration-Resistant Prostate CancerPrinter Friendly Version
11/25/14Exelixis to Present at the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, December 2Printer Friendly Version
11/16/14Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and VemurafenibPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation2013 Annual Report (pdf)
Download Documentation2012 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.